Publications:
Our Research

Filter

Filter

Research Area
Technology
Resource type
Category
222 results found
Nov 9, 2024
Publication
Novavax led
ScienceDirect
COVID-19, Matrix-M® adjuvant
Relative effectiveness of homologous NVX-CoV2373 and BNT162b2 COVID-19 vaccinations in South Korea
Eunseon Gwak, Seung-Ah Choe, Erdenetuya Bolormaa, et al.
Nov 8, 2024
Pre-print
Novavax led
medRxiv
COVID-19, Matrix-M® adjuvant
Safety and Immunogenicity of Omicron Protein Vaccines in mRNA-Vaccinated Adolescents: A Phase 3, Randomised Trial
Chijioke Bennett, Gordon Chau, Erika Clayton et al.
Nov 8, 2024
Pre-print
Novavax led
medRxiv
COVID-19, Matrix-M® adjuvant
Adjuvant Recombinant SARS-CoV-2 Spike Protein Vaccine Immunogenicity After Prior mRNA Vaccine Doses
Jeffrey M Adelglass, Paul Bradley, Miranda R Cai et al.
Nov 4, 2024
Publication
Collaborative
Journal of Virology
COVID-19, Matrix-M® adjuvant
Immunogenicity and efficacy of XBB.1.5 rS vaccine against the EG.5.1 variant of SARS-CoV-2 in Syrian hamsters
Soudani N, Bricker TL, Darling T, et al.
Nov 4, 2024
Pre-print
Novavax led
medRxiv
COVID-19, Matrix-M® adjuvant
Immunogenicity and safety of a monovalent Omicron XBB.1.5 SARS-CoV-2 recombinant spike protein vaccine in previously unvaccinated, SARS-CoV-2 seropositive participants: primary day-28 analysis of a phase 2/3 open-label study
Katia Alves, Alex Kouassi, Joyce S Plested et al.
Oct 16, 2024
Publication
Novavax led
JMIR public health and surveillance
COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment
David Salisbury, Jeffrey V Lazarus, Nancy Waite, et al.
Oct 16, 2024
Publication
Collaborative
JMIR public health and surveillance
COVID-19, Matrix-M® adjuvant
COVID-19 Vaccine Preferences in General Populations in Canada, Germany, the United Kingdom, and the United States: Discrete Choice Experiment
Salisbury D, Lazarus JV, Waite N, et al.
Oct 15, 2024
Publication
Collaborative
Journal of Infection
COVID-19, Matrix-M® adjuvant
Mechanisms and Implications of IgG4 Responses to SARS-CoV-2 and Other Repeatedly Administered Vaccines
Marchese AM, Fries L, Beyhaghi H, et al.
Oct 11, 2024
Pre-print
Novavax led
Seasonal influenza, Matrix-M® adjuvant
A Modified Novel Validated High-Throughput Hemagglutinin Inhibition Assay Using Recombinant Virus-Like Particles and Human Red Blood Cells for the Objective Evaluation of Recombinant Hemagglutinin Nanoparticle Seasonal Influenza Vaccine
Timothy S. Vincent, Mingzhu Zhu, Anand Parekh, et al.
Sep 27, 2024
Publication
Novavax led
Journal of Infection
COVID-19, Matrix-M® adjuvant
Immunogenicity and Safety of SARS-CoV-2 Recombinant Spike Protein Vaccine in South African People Living With and Without HIV-1 Infection: A Phase 2 Randomised Trial
Chijioke Bennett, Zaheer Hoosain, Anthonet Koen, et al.